News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences buys BMEYE for $42 mil. Sapien valve sales in Q3 fall below firm’s expectations. Hospira draws FDA warning letter. More news briefs.
You may also be interested in...
FDA Clears Edwards’ Non-Invasive Hemodynamic Monitor For High-Risk Surgical Patients
ClearSight is intended to reduce the risk of post-surgical complications by non-invasively monitoring blood volume and flow based on information gathered by a small finger cuff with an infrared sensor.
FDA Hits Baxter With Two Warning Letters In Four Weeks
The warning letters cite quality system regulation violations related to the firm’s infusion pumps, including inadequate corrective and preventive actions related to complaints of over-infusion and device bladder ruptures.
Reimbursement Briefs: OIG Looks At DME; AHRQ Seeks Imaging Info; MolDx News
OIG announces investigation of Medicare’s competitive bidding program in four states and, separately, finds inappropriate and questionable CMS billing for diabetes test strips. AHRQ seeks information about imaging tests for diagnosis and staging of pancreatic cancer. More reimbursement news.